Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase1. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma1, 2, 3, 4, 5. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway2, 3. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways6, 7. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy8, 9. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.
- Research Organization:
- Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
- Sponsoring Organization:
- INDUSTRY
- OSTI ID:
- 1404986
- Journal Information:
- Nature (London), Journal Name: Nature (London) Journal Issue: 7610 Vol. 535; ISSN 0028-0836
- Publisher:
- Nature Publishing Group
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
Dual Allosteric Inhibition of SHP2 Phosphatase
Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2
Journal Article
·
Tue Oct 30 04:00:00 UTC 2018
· Nature Communications
·
OSTI ID:1481293
Dual Allosteric Inhibition of SHP2 Phosphatase
Journal Article
·
Fri Jan 05 00:00:00 UTC 2018
· ACS Chemical Biology
·
OSTI ID:1435825
Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2
Journal Article
·
Wed Mar 18 00:00:00 UTC 2020
· Journal of Biological Chemistry
·
OSTI ID:1630331